TP53 and small cell lung carcinoma: The result of this preclinical study has been translated into the clinic in an ongoing phase II clinical trial of onvansertib in relapsed SCLC (NCT05450965) where YAP1 expression and inactivating TP53 gene mutations will be interrogated as potential biomarkers to guide future clinical studies.